RLY-2608 + Fulvestrant + Palbociclib 125mg + Ribociclib 400mg + Ribociclib 600mg + PF-07220060 100mg + PF-07220060 300 mg
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
PIK3CA Mutation
Conditions
PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor
Trial Timeline
Dec 8, 2021 → Apr 30, 2027
NCT ID
NCT05216432About RLY-2608 + Fulvestrant + Palbociclib 125mg + Ribociclib 400mg + Ribociclib 600mg + PF-07220060 100mg + PF-07220060 300 mg
RLY-2608 + Fulvestrant + Palbociclib 125mg + Ribociclib 400mg + Ribociclib 600mg + PF-07220060 100mg + PF-07220060 300 mg is a phase 1 stage product being developed by Relay Therapeutics for PIK3CA Mutation. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05216432. Target conditions include PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer.
What happened to similar drugs?
0 of 1 similar drugs in PIK3CA Mutation were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05216432 | Phase 1 | Recruiting |
Competing Products
13 competing products in PIK3CA Mutation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Miransertib | Merck | Phase 2 | 39 |
| Miransertib | Merck | Phase 1/2 | 24 |
| Alpelisib | Novartis | Phase 2 | 42 |
| Alpelisib | Novartis | Phase 2 | 39 |
| Alpelisib + Placebo | Novartis | Phase 2 | 39 |
| alpelisib | Novartis | Pre-clinical | 30 |
| BYL719 + Fulvestrant | Novartis | Phase 1 | 29 |
| BYL719 + AMG 479 | Novartis | Phase 1/2 | 24 |
| Inavolisib + Atezolizumab + Pembrolizumab | Roche | Phase 1 | 36 |
| CGT6297 | Cogent Biosciences | Phase 1 | 33 |
| RLY-5836 + Fulvestrant + Palbociclib + Ribociclib + Abemaciclib | Relay Therapeutics | Phase 1 | 23 |
| RLY-2608 + Placebo | Relay Therapeutics | Phase 2 | 36 |
| RLY-2608 + Capivasertib + Fulvestrant | Relay Therapeutics | Phase 3 | 41 |